Media

Filter by Year:

Immuron (ASX:IMC) tables 494pc increase in North American FY22 Travelan sales

11 July 2022

Biopharmaceutical company Immuron (IMC) has seen a 494 per cent increase in North American Travelan sales for FY22.

Immuron (ASX:IMC) enters research agreement with Monash University

15 December 2020

Immuron (IMC) has entered a research agreement with Monash University to evaluate the efficacy of IMM-124E and advance SARS-CoV-2 findings.

Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?

21 July 2020

Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.

Immuron reveals anti-COVID potential, raises $28 million

20 July 2020

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.

Diarrhea: A major health issue for Americans travelling abroad

12 February 2020

Research surveys have shown that around one in four travellers changes their travel itinerary due to diarrhoea and around 5% have to seek medical attention.

Walter Reid Army Institute of Research 2019 Year in Review

15 January 2020

The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.

Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)

1 January 2020

The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.

Travelan on The Not Old Better Show with Dr. Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research WRAIR

1 June 2019

Travelan featured on The Not Old Better Show with Dr.Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research. Dr Hailey is currently engaged in the investigation of immune responses to Shigella vaccines in pre-clinical/ human clinical

Immuron CEO interviewed on the RedChip Money Report, USA

10 October 2018

Immuron CEO - Dr Jerry Kanellos interviewed on the Red Chip Money Report, USA. Immuron: Developing Innovative Immunotherapy Therapies for Gut-Mediated Diseases

No crap: Immuron is one step closer to an anti-gastro pill

16 July 2018

In January, Immuron (ASX:IMC) released a study of its Travelan tablets by the DOD which showed its was effective in preventing travellers diarrhoea in 180 strains of campylobacter.

Big Pharma is watching as Immuron edges towards trial results

26 June 2018

There’s no arguing against the ‘breast is best’ mantra at long-standing Melbourne based biotech Immuron, which bases its therapeutics on the goodness of colostrum (the antibody-rich milk produced by mammals after birth).

Immuron reduces liver inflammation

2 March 2018

Immuron Limited (ASX: IMC) said results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study were positive. Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharid

How Do You Recruit Patients Unaware Of Their Disease?

1 March 2018

Immuron’s anti-NASH drug is IMM-124E, a colostrum-based compound. Colostrum is the first secretion (milk) from the mammary glands of cows post birth. Colostrum tends to be high in antibodies, although Immuron uses a very specific kind of colostrum achieve

Immuron's fatty liver disease candidate advancing — 4 insights

14 September 2017

Immuron is making progress on three clinical trials for IMM-124E, its nonalcoholic steatohepatitis and nonalcoholic fatty liver disease treatment. Here's what you should know.

In dash to NASH, Immuron targets the gut not the liver

28 March 2017

Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.